Loading…

Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients

Background/Aims Autoimmune Hepatitis (AIH) is a liver disease which may lead to liver cirrhosis. Cirrhosis is a well-known risk factor for hepatocellular cancer. Lymphoma is a disease, where immune modulating drugs as well as the autoimmune disease itself may contribute to the elevated risk. The aim...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2009-02, Vol.50 (2), p.388-393
Main Authors: Werner, Mårten, Almer, Sven, Prytz, Hanne, Lindgren, Stefan, Wallerstedt, Sven, Björnsson, Einar, Bergquist, Annika, Sandberg-Gertzén, Hanna, Hultcrantz, Rolf, Sangfelt, Per, Weiland, Ola, Danielsson, Åke
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims Autoimmune Hepatitis (AIH) is a liver disease which may lead to liver cirrhosis. Cirrhosis is a well-known risk factor for hepatocellular cancer. Lymphoma is a disease, where immune modulating drugs as well as the autoimmune disease itself may contribute to the elevated risk. The aim was to investigate the risks of malignancies in a large cohort of AIH patients. Methods Four hundred and seventy-three patients with AIH were matched to the Swedish national cancer register as well as to the death cause register. Results We found an overall higher risk of malignancies in the cohort of AIH patients from the date of diagnosis with a SIR of 1.51 (95% CI 1.10–2.03). SIR in the subpopulation of well defined catchment areas and complete case finding was 23.28 (95% CI 7.5–54.34) for HCC. Lymphomas were found a SIR of 13.09 (95% CI 4.22–30.56). Conclusions There was an overall increased risk of malignancies in a cohort of AIH patients, which manly was caused by hepatobiliary cancers. However, the true risk of HCC in an AIH cirrhotic cohort has yet to be investigated. A significantly higher risk of lymphomas was also found, but no clear cut association to the use of immune modulators.
ISSN:0168-8278
1600-0641
1600-0641
DOI:10.1016/j.jhep.2008.08.022